Literature DB >> 34128469

Eruptive xanthoma model reveals endothelial cells internalize and metabolize chylomicrons, leading to extravascular triglyceride accumulation.

Ainara G Cabodevilla1, Songtao Tang1, Sungwoon Lee2, Adam E Mullick3, Jose O Aleman1, M Mahmood Hussain4, William C Sessa2, Nada A Abumrad5, Ira J Goldberg1.   

Abstract

Although tissue uptake of fatty acids from chylomicrons is primarily via lipoprotein lipase (LpL) hydrolysis of triglycerides (TGs), studies of patients with genetic LpL deficiency suggest additional pathways deliver dietary lipids to tissues. Despite an intact endothelial cell (EC) barrier, hyperchylomicronemic patients accumulate chylomicron-derived lipids within skin macrophages, leading to the clinical finding eruptive xanthomas. We explored whether an LpL-independent pathway exists for transfer of circulating lipids across the EC barrier. We found that LpL-deficient mice had a marked increase in aortic EC lipid droplets before and after a fat gavage. Cultured ECs internalized chylomicrons, which were hydrolyzed within lysosomes. The products of this hydrolysis fueled lipid droplet biogenesis in ECs and triggered lipid accumulation in cocultured macrophages. EC chylomicron uptake was inhibited by competition with HDL and knockdown of the scavenger receptor-BI (SR-BI). In vivo, SR-BI knockdown reduced TG accumulation in aortic ECs and skin macrophages of LpL-deficient mice. Thus, ECs internalize chylomicrons, metabolize them in lysosomes, and either store or release their lipids. This latter process may allow accumulation of TGs within skin macrophages and illustrates a pathway that might be responsible for creation of eruptive xanthomas.

Entities:  

Keywords:  Endocrinology; Lipoproteins; Metabolism

Mesh:

Substances:

Year:  2021        PMID: 34128469      PMCID: PMC8203467          DOI: 10.1172/JCI145800

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   19.456


  73 in total

1.  Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Authors:  Anne P Beigneux; Kazuya Miyashita; Michael Ploug; Dirk J Blom; Masumi Ai; MacRae F Linton; Weerapan Khovidhunkit; Robert Dufour; Abhimanyu Garg; Maureen A McMahon; Clive R Pullinger; Norma P Sandoval; Xuchen Hu; Christopher M Allan; Mikael Larsson; Tetsuo Machida; Masami Murakami; Karen Reue; Peter Tontonoz; Ira J Goldberg; Philippe Moulin; Sybil Charrière; Loren G Fong; Katsuyuki Nakajima; Stephen G Young
Journal:  N Engl J Med       Date:  2017-04-05       Impact factor: 91.245

2.  Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis.

Authors:  Tom Kirchhausen; Eric Macia; Henry E Pelish
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

3.  The tissue distribution of lipoprotein lipase determines where chylomicrons bind.

Authors:  Roger Savonen; Michaela Hiden; Magnus Hultin; Rudolf Zechner; Sanja Levak-Frank; Gunilla Olivecrona; Thomas Olivecrona
Journal:  J Lipid Res       Date:  2015-01-14       Impact factor: 5.922

Review 4.  SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux.

Authors:  Wen-Jun Shen; Salman Azhar; Fredric B Kraemer
Journal:  Annu Rev Physiol       Date:  2017-11-10       Impact factor: 19.318

5.  Adipose-specific lipoprotein lipase deficiency more profoundly affects brown than white fat biology.

Authors:  Itsaso Garcia-Arcos; Yaeko Hiyama; Konstantinos Drosatos; Kalyani G Bharadwaj; Yunying Hu; Ni Huiping Son; Sheila M O'Byrne; Chuchun L Chang; Richard J Deckelbaum; Manabu Takahashi; Marit Westerterp; Joseph C Obunike; Hongfeng Jiang; Hiroaki Yagyu; William S Blaner; Ira J Goldberg
Journal:  J Biol Chem       Date:  2013-03-31       Impact factor: 5.157

6.  LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice.

Authors:  K C Yu; W Chen; A D Cooper
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins.

Authors:  M Mulder; P Lombardi; H Jansen; T J van Berkel; R R Frants; L M Havekes
Journal:  Biochem Biophys Res Commun       Date:  1992-06-15       Impact factor: 3.575

8.  A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis.

Authors:  Masako Ueda; Richard L Dunbar; Anna Wolska; Tracey U Sikora; Maria Del Rosario Escobar; Naomi Seliktar; Emil deGoma; Stephanie DerOhannessian; Linda Morrell; Adam D McIntyre; Frances Burke; Denis Sviridov; Marcelo Amar; Robert D Shamburek; Lita Freeman; Robert A Hegele; Alan T Remaley; Daniel J Rader
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

9.  Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages.

Authors:  S C Rumsey; J C Obunike; Y Arad; R J Deckelbaum; I J Goldberg
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 10.  Abetalipoproteinemia: two case reports and literature review.

Authors:  Rola Zamel; Razi Khan; Rebecca L Pollex; Robert A Hegele
Journal:  Orphanet J Rare Dis       Date:  2008-07-08       Impact factor: 4.123

View more
  3 in total

Review 1.  Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function.

Authors:  Yu Ding; Yongwen Zhou; Ping Ling; Xiaojun Feng; Sihui Luo; Xueying Zheng; Peter J Little; Suowen Xu; Jianping Weng
Journal:  Theranostics       Date:  2021-09-09       Impact factor: 11.556

Review 2.  Targeting the vasculature in cardiometabolic disease.

Authors:  Nabil E Boutagy; Abhishek K Singh; William C Sessa
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808

3.  Lysosomal acid lipase promotes endothelial proliferation in cold-activated adipose tissue.

Authors:  Alexander W Fischer; Michelle Y Jaeckstein; Joerg Heeren
Journal:  Adipocyte       Date:  2022-12       Impact factor: 4.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.